MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - November 24, 2009) -
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its co-founder and CEO Dr. Simon Moroney was awarded the Bavarian State Medal for Outstanding Services to the Bavarian Economy. The award ceremony took place at the Bavarian State Ministry of Economy, Infrastructure, Transport and Technology in Munich, Germany, on November 23, 2009.
“I am pleased to award Dr. Moroney the Bavarian State Medal for Outstanding Services for his contribution to the Bavarian biotechnology sector and the Bavarian economy in general”, commented Martin Zeil, Bavarian State Ministry of Economy, Infrastructure, Transport and Technology. “MorphoSys is a success story in the German biotech landscape and acts as a key factor for Munich’s endeavors to become a leading biotechnology region. Thanks to the sustainable business model Dr. Moroney is pursuing with MorphoSys, the company was able to provide new jobs even in these challenging markets.”
Since being founded in 1992, MorphoSys has been one of the most closely followed German biotechnology companies. From its start as a core team of young researchers, it has grown into a globally operating organization with some 400 employees. Within the biotechnology sector, MorphoSys is viewed as a technology leader and the partner of choice for antibody development.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation, within which it plans to have eight active programs by the end of 2009. Its most advanced program is MOR103, a first-in-class, fully human antibody against GM-CSF. MorphoSys expects to commence a Phase Ib/IIa trial of this antibody in rheumatoid arthritis patients in the second half of 2009. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol “MOR”. For further information, visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registered trademarks of MorphoSys AG
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone: +49 (0) 89 / 899 27-122 claudia.gutjahr-loeser@morphosys.com Mario Brkulj Senior Manager Corporate Communications & IR Phone: +49 (0) 89 / 899 27-454 mario.brkulj@morphosys.com Jessica Kulpi Specialist Corporate Communications & IR Phone: +49 (0) 89 899 27 332 jessica.kulpi@morphosys.com
Press Release (PDF): http://hugin.info/130295/R/1356844/329880.pdf
Picture_Moroney_Zeil: http://hugin.info/130295/R/1356844/329897.jpg
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
